1 citations
,
November 2010 in “Anticancer Research” Finasteride and dutasteride both increase chromogranin A levels similarly.
May 2026 in “Reactions Weekly” Finasteride and dutasteride may increase the risk of suicide and sexual dysfunction.
Finasteride and dutasteride can harm male reproductive health, affecting sperm and causing sexual dysfunction.
April 2026 in “Brain Sciences” Finasteride may cause depression and suicidal thoughts, especially in young men.
February 2026 in “Skin Appendage Disorders” Scalp microinfusion with dutasteride is a safe and promising treatment for male hair loss.
February 2026 in “Journal of Drugs in Dermatology” Dutasteride mesotherapy for hair loss can cause lasting bald patches.
January 2026 in “Reactions Weekly” Both finasteride and dutasteride can cause sexual side effects, but they may differ in frequency and severity.
January 2026 in “Cronfa (Swansea University)” Finasteride and dutasteride may increase the risk of depression and suicidality, so patients should be monitored closely.
January 2026 in “Pharmaceutical journal/The pharmaceutical journal” Finasteride and dutasteride now have stronger warnings for psychiatric and sexual side effects.
December 2025 in “The AAPS Journal” Finasteride and dutasteride's effects are mainly due to target binding saturation and slow enzyme turnover.
December 2025 in “Journal of Cosmetic Dermatology” Intralesional dutasteride improves hair growth in androgenic alopecia with minimal side effects.
October 2025 in “Reactions Weekly” Finasteride and dutasteride may cause depression and suicidal thoughts.
September 2025 in “Dermatology and Therapy” The treatment improved hair growth and was well-received without side effects.
July 2025 in “Skin Appendage Disorders” Dutasteride microinfusion and microneedling both effectively treat male hair loss.
June 2025 in “Pharmaceutics” Ethosomes with 30% ethanol effectively deliver dutasteride to hair follicles for treating hair loss.
June 2025 in “Journal of Drug Delivery Science and Technology” A dissolving microneedle patch with dutasteride offers effective, long-lasting hair loss treatment with fewer side effects.
March 2025 in “Journal of the American Academy of Dermatology” Dutasteride and finasteride do not increase mood disorder risk in men with hair loss.
March 2025 in “Daehan saengsik uihak hoeji/Clinical and experimental reproductive medicine” Long-term use of dutasteride for hair loss may harm semen quality.
February 2025 in “JAAD International” Five monthly sessions of minoxidil-dutasteride-copper peptide tattooing significantly improve hair regrowth in men with androgenetic alopecia.
January 2025 in “Journal of the American Academy of Dermatology” Low-dose oral minoxidil alone is effective for treating hair loss, but combining it with dutasteride or finasteride may offer better results.
January 2025 in “Expert Opinion on Pharmacotherapy” Dutasteride is more effective than finasteride for hair loss but may affect male fertility and should be used cautiously.
January 2025 in “Lasers in Medical Science” Combining fractional CO2 laser with topical dutasteride is more effective for treating male hair loss than using the laser alone.
January 2025 in “Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)” Skin patting and iontophoresis with dutasteride gel improved hair growth in people with androgenetic alopecia.
Dutasteride may become the top choice for treating hair loss.
December 2024 in “Zanco Journal of Medical Sciences” Finasteride and dutasteride are equally effective and safe for treating BPH.
December 2024 in “Journal of Pharmaceutical Research International” The gel effectively delivers dutasteride for hair loss treatment and remains stable for 90 days.
December 2024 in “Therapeutic Delivery” Topical dutasteride shows promise for hair loss but needs more research.
November 2024 in “Pharmaceutics” Transfersomes are better than liposomes for targeting hair follicles in alopecia treatment.
November 2024 in “Nanomaterials” The nanocrystalline suspension effectively delivers dutasteride over time with minimal inflammation.
October 2024 in “JAAD Case Reports” Dutasteride mesotherapy showed mixed results and is not recommended as a primary treatment for hair loss.